Repligen Corp

RGEN

Company Profile

  • Business description

    Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

  • Contact

    41 Seyon Street
    Building 1, Suite 100
    WalthamMA02453
    USA

    T: +1 781 250-0111

    E: [email protected]

    https://www.repligen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2026

    Employees

    2,000

Stocks News & Analysis

stocks

Magellan merger modestly dilutive

Our view on how shareholders should respond to the Magellan merger.
stocks

ASX listed gold miner under pressure due to lower production

Shares have dropped nearly 20% since lowering 2026 volume guidance.
stocks

3 ASX opportunities after earnings season

Uncovering key opportunities following February’s results.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,847.7014.200.16%
CAC 407,967.317.18-0.09%
DAX 4023,581.87149.05-0.63%
Dow JONES (US)46,993.2646.850.10%
FTSE 10010,329.8973.71-0.71%
HKSE26,025.42156.880.61%
NASDAQ22,479.53105.350.47%
Nikkei 22555,239.401,539.012.87%
NZX 50 Index13,315.60133.371.01%
S&P 5006,716.090.000.00%
S&P/ASX 2008,640.6014.400.17%
SSE Composite Index4,062.9813.080.32%

Market Movers